Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: results of a multidisciplinary international expert panel (EPACT II)

TitreAppropriate therapy for fistulizing and fibrostenotic Crohn's disease: results of a multidisciplinary international expert panel (EPACT II)
Publication TypeConference Paper
Year of Publication2009
AuthorsFelley, C, Vader, J-P, Juillerat, P, Pittet, V, Gonvers, J-J, Mottet, C, Froehlich, F, Michetti, P
Conference NameGASTRO 2009
PublisherUnited European Gastroenterology Week, London
Conference LocationNovember 21 -25, 2009, London
ISBN Number0017-5749
Accession Numberserval:BIB_34914037467D
Mots-clésCrohn Disease/complications, Crohn Disease/therapy, International Cooperation, Practice Guidelines as Topic
Abstract

Introduction
Many therapeutic decisions in the management of fistulizing and fibrostenotic Crohn's disease (CD) have to be taken without the benefit of strong scientific evidence. For this reason, explicit appropriateness criteria for CD fistula and stenosis treatment were developed by a multidisciplinary European expert panel in 2004 with the aim of making them easily available on the Internet and thus allowing individual case scenario evaluation; these criteria were updated in 2007.
Methods
Twelve international experts convened in Geneva, Switzerland in December 2007. Explicit clinical scenarios, corresponding to real daily practice, were rated on a 9-point scale based on evidence from the published literature and panelists' own expertise. Median ratings were stratified into three categories: appropriate (7-9), uncertain (4-6) and inappropriate (1-3).
Results
Overall, panelists rated 60 indications pertaining to fistulas. Antibiotics, azathioprine/6-mercaptopurine and conservative surgery are the mainstay of therapy for simple and complex fistulas. In the event of previous failure of azathioprine/6-mercaptopurine therapy, methotrexate and infliximab were considered appropriate for complex fistulas. The panel also rated 72 indications related to the management of fibrostenotic CD. The experts considered balloon dilation, if the stricture was endoscopically accessible, stricturoplasty and bowel resection to be appropriate for small bowel fibrostenotic Crohn's disease, and balloon dilation and bowel resection appropriate for fibrostenotic colonic disease. In the presence of an ileocolonic or ileorectal anastomotic stricture of Conclusion
Antibiotics, azathioprine/6-mercaptopurine, and conservative surgery are the mainstay of therapy for fistulizing Crohn's disease. Infliximab is a therapeutic option in patients without prior response to immunosuppressant therapy. In fibrostenotic Crohn's disease, endoscopic balloon dilation, if feasible, or surgical therapy should be considered. These expert recommendations are available online (www.epact.ch). Prospective evaluation is now needed to test the validity of these appropriateness criteria in clinical practice.

Notes

oai:serval.unil.ch:BIB_34914037467D

URLhttp://www.smw.ch/docs/PdfContent/smw-12563.pdf
WOS ID (UT)

Publié

Citation Key / SERVAL ID3981
ÉtiquetteUnited European Gastroenterology Week, London

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | iumsp@chuv.ch

Go to top